Objectives -To compare demographic data, disease severity and response to therapy between ALD and AD dogs.
Introduction
In humans, atopic dermatitis (AD) has been traditionally classified into two subtypes according to the level of serum total IgE and the presence of specific IgE against environmental and food allergens. The intrinsic type (IAD), also named nonallergic AD, nonatopic eczema, atopiform dermatitis or nonallergic atopic eczema/dermatitis syndrome, 1 is characterized by low or normal serum total IgE levels and negative allergen-specific IgE reactions to common environmental and food allergens, in the serum and skin prick test. [1] [2] [3] [4] The extrinsic type of AD (EAD) or allergic atopic eczema/AD is characterized by high serum total IgE levels and positive allergen-specific IgE to common environmental and food allergens. 1, 2 It has been hypothesized that IAD and EAD are different stages of AD. The condition in infancy may begin as nonallergic (IAD) and progress to atopy (EAD) overtime. [5] [6] [7] This hypothesis has been supported by two studies that reported allergen sensitization with positive allergen-specific IgE in a number of patients initially diagnosed as IAD. 1, 8 Canine atopic-like dermatitis (ALD) has been defined as an inflammatory and pruritic skin disease with clinical features identical to those seen in canine AD, in which an IgE response to environmental or other allergens cannot be documented. 9, 10 Because total serum IgE levels have a poor correlation with the atopic status in dogs, [11] [12] [13] this parameter cannot be used to distinguish AD and ALD in dogs. Thus, in dogs, the differentiation has been made on the basis of the results of intradermal (IDT) and serum allergen-specific IgE tests (AST).
To the best of the authors' knowledge, there is only one study, published as an abstract, contrasting the clinical and epidemiological features of canine AD versus ALD.
14 Several other studies [15] [16] [17] have investigated different aspects of ALD; however, the diagnosis was made based on either IDT or serum test, not strictly both. The primary aim of this retrospective study was to compare, in a population of dogs diagnosed with AD or ALD using both the IDT and AST tests, the following: (i) demographic data; (ii) disease severity measured by pruritus level, number of body sites affected and treatment and (iii) response to therapy measured by reduction in pruritus level and number of body sites affected during treatment. The secondary aim was to summarize the demographic data of all dogs included in the study.
Methods and materials

Medical record search and data collection
Medical records of dogs seen in a veterinary teaching hospital from 2007 to 2015 were searched using the keywords as follows: atopic dermatitis, atopy, allergy, dog and canine. Inclusion criteria for eligible dogs were (i) diagnosis of AD; (ii) IDT and AST test results available, and (iii) IDT and AST tests performed on the same day. Exclusion criteria were (i) dogs with nonseasonal clinical signs of AD with no records of an elimination diet trial performed; and (ii) dogs assigned to the ALD group that had a positive response to a food trial (because this could represent an IgE-mediated allergic response). Data collected from each dog included sex, breed, age of disease onset, seasonality, presence of respiratory signs, presence of conjunctivitis, performance of food trial, food trial response, percentage of time spent indoors, body regions affected, pruritus level and treatment. A standard history questionnaire was part of the electronic medical record (UVIS â , Universal Veterinary Information System, Ross Group Inc.; Miamisbur, OH, USA); therefore, the listed information was documented consistently for all cases.
Intradermal and serum allergen-specific IgE test protocols
The IDT test was performed by clipping the dog's lateral thorax and injecting in the dermis 0.1 mL of 60 environmental allergens (Stallergenes Greer â ; Lenoir, NC, USA). The reactions were evaluated 15 min after the injections and subjectively graded 0 to 4+ based on the negative (saline) and positive (1:100,000 histamine) controls. The dogs were sedated for the test using dexmedetomidine hydrochloride (Orion Corp.; Espoo, Finland) intravenously at the dose of 0.004 mg/kg. Drug withdrawal time prior to IDT was as follows: two weeks for antihistamines, essential fatty acids and topical products containing glucocorticoids, four weeks for oral glucocorticoids, ciclosporin and oclacitinib and, six to eight weeks for injectable glucocorticoids.
Approximately 3 mL of blood was collected for the AST and placed in serum separator glass tubes. The serum was separated by centrifugation and stored refrigerated under 2-4°C until submission to the laboratory within 12 h of collection. The AST was performed by IDEXX reference laboratories (IDEXX Laboratories, Inc.; Westbrook, MA, USA) using the Greer Aller-g-complete â kit (Stallergenes Greer â ). A monoclonal antibody cocktail-based ELISA was used for the detection of serum allergen-specific IgE, as described previously. 18 The allergen panel used in the IDT and AST included household allergens, moulds and pollens of trees, grasses and weeds (Tables  S1 & S2, respectively) .
Study population
Dogs were placed into the AD or ALD group based on their IDT and AST results. The dogs that did not show any positive reactions on both the IDT and AST were classified as ALD. The ones that showed one or more positive reactions on one or both tests were placed in the AD group. To be considered positive on the IDT, any reaction had to have a 2+ or higher score, and be associated with erythema and skin turgidity. 9 To be considered positive on the AST, the reaction had to be ≥80 EAU (ELISA absorbance units) as reported by IDEXX Laboratories.
Statistical analyses
All dogs were included in the demographic data analysis. However, for all other analyses, only dogs with at least four follow-up visits were included because this was considered to be a reasonable minimal number of visits necessary to determine the maintenance treatment regimen and evaluate response to therapy. Means and standard deviations were used to report the time period to achieve four follow-up visits, the maximum duration of the follow-up period and the number of follow-up visits.
Descriptive statistics was used to characterize the demographic variables in each group in addition to the groups combined. Means were compared between the AD and ALD groups using the chi-square test or Fisher's exact test for the qualitative data and the Wilcoxon-Mann-Whitney U-test for the quantitative data. To determine whether there was breed predisposition to develop AD or ALD, breed frequency was compared between each group and the general canine hospital population seen during the study period, using Fisher's exact test.
In order to assess differences in disease severity, the mean pruritus level and number of body sites affected at the first visit were compared between the AD and ALD groups using the WilcoxonMann-Whitney U-test. In order to standardize the information available in the medical records, the dog's body surface was divided as follows: face, ears, neck, thorax, dorsum, flanks, abdomen, axillae, groins, front legs, hind legs, front paws, hind paws, perineum and tail. Each of these body sites was counted as one affected area, totalling 16 sites. The pruritus level recorded in the medical records was based on a 0-10 scoring system using owner's verbal assessment (before 2009) or the pruritus Visual Analog Scale (pVAS) as reported previously (after 2009). 19 The dog's pruritus level at the first visit also was evaluated by categorizing the scores in severity levels according to the recommendations of the International Committee on Allergic Diseases of Animals (ICADA) as follows: mild: 2.0-3.5; moderate: 3.6-5.5 and severe: 5.6-10). 20 The frequency of each severity score was compared between the groups using Fisher's exact test. Additionally, to indirectly assess disease severity, the maintenance treatment modalities were scored and compared between the AD and ALD groups using Fisher's exact test. The following empirical treatment scoring system was developed and used in the analysis: 1 (antihistamines and/or essential fatty acids and/or allergen-specific immunotherapy); 2 [one immunomodulatory agent (i.e. oral glucocorticoid, ciclosporin, oclacitinib or lokivetmab) with or without one or more of the medications included in score 1] and 3 (two or more immunomodulatory drugs, with or without one or more of the medications included in score 1). We considered maintenance treatment to be the most frequently used protocol that controlled the disease and this was determined as the average treatment scores during four or more follow-up visits.
In order to assess differences in response to therapy, the mean pruritus scores and mean number of body sites affected during treatment were compared between the ALD and AD groups using the Wilcoxon-Mann-Whitney U-test. The pruritus scores were then categorized in severity levels as described above, and the frequency of each severity score was compared between the groups using Fisher's exact test. Because there were no significant differences between the groups in the number of dogs in each of the maintenance treatment scores, the analysis was not blocked by treatment scores. The reduction of pruritus scores and number of lesions overtime also were compared between the groups to measure differences in therapy responses using a marginal linear regression model.
All statistical analyses were performed using the software R v.3.2.4 (R Core Team. R: A Language and Environment for Statistical Computing. http://www.R-project.org; R Foundation for Statistical Computing, Vienna, Austria, 2014). A P-value ≤0.05 was considered significant.
Results
Demographic data A total of 2,691 cases were initially retrieved, and 253 were considered eligible for the study based on the inclusion and exclusion criteria. Two hundred and sixteen (85.38%) dogs were included in the AD group and 37 (14.62%) in the ALD group. There were no significant differences between the groups in the demographic variables presented in Table 1 . The proportion of males (51.4%; 51.4%) and females (48.6%; 48.6%), respectively, in the ALD and AD groups was identical (P = 0.997). There were no significant differences in the age of disease onset (ALD: 16.2 months; AD: 20.9 months; P = 0.232). The respiratory signs recorded in the medical records were sneezing, coughing and running nose. The most common respiratory sign in the ALD and AD groups was sneezing. The proportion of dogs with respiratory signs was low in both groups (ALD: 24.3%; AD: 19.0%; P = 0.317), as was the frequency of dogs with conjunctivitis (ALD: 21.6%; AD: 18.1%; P = 0.648). Clinical signs of AD were predominantly yearround in the ALD and AD groups (70.3%; 60.2%; P = 0.244) and the dogs in each group spent on average >80% of the time indoors (ALD: 87.0%; AD: 83.5%; P = 0.385).
A strict food elimination diet trial followed by challenge was performed in 222 of 253 dogs (87.7%), and a partial positive response was observed in 25 of 253 dogs (11.3%), all from the AD group. The 31 dogs that did not have a food trial performed (26 AD and 5 ALD) had strictly seasonal clinical signs (Table 1) .
There were 34 of 216 (13.4%) dogs with positive serology and negative intradermal test results in the AD group.
When all study dogs were compared to the general hospital population seen during 2007 and 2015, the softcoated wheaten terrier (P < 0.000; OR = 5.8), American Staffordshire terrier (P < 0.000; OR = 4.76), English bulldog (P = 0.005; OR = 3.49) and the Labrador retriever (P = 0.037; OR = 1.40) were predisposed to developing AD. Breeds over-represented in the AD group also included the soft-coated wheaten terrier (P < 0.001; OR = 5.8), American Staffordshire terrier (P < 0.000; OR = 5.61), English bulldog (P = 0.002; OR = 4.11) and the Labrador retriever (P = 0.024; OR = 1.46). There were no over-represented breeds in the ALD group when compared to the general hospital population seen during the study period.
For the analyses of disease severity and response to therapy, 171 dogs with records of at least four followup visits were included. The mean time period to achieve four follow-up visits was 5.1 months (SD: 1.7; range: 2-11), and the maximum duration of the followup period was eight years (mean: 3.0 years; SD: 1.9 years; range: four months to eight years). The mean number of follow-up visits was 6.7 (SD: 2.39; range four to 18).
Comparison of disease severity between the AD and ALD groups
The pruritus scores and number of affected body sites of dogs at the first visit and the maintenance therapy protocols across visits were used as parameters to assess disease severity in the groups. There was no significant difference (Wilcoxon-Mann-Whitney U-test, P = 0.433) in the mean pruritus score of dogs in the AD (6.5 AE 2.1; range: 0-10) and ALD (6.87 AE 1.86; range: 2-9) groups (Figure 1a) . When pruritus scores were categorized in severity levels, most dogs in the AD (70.4%) and ALD (81.2%) groups had severe pruritus. There were no significant differences between the groups (Fisher's exact test; P = 0.908) in the frequencies of cases classified as having mild, moderate or severe pruritus levels (Figure 1b) .
There was no significant difference (Wilcoxon-MannWhitney U-test; P = 0.474) in the mean number of affected body sites between the AD (3.8 AE 1.8; range: 0-11) and the ALD (3.7 AE 2.6; range = 0-8) groups (Figure 2) . No significant differences (Fisher's exact test; P = 0.796) in the frequencies of dogs receiving each of the categorized maintenance treatment modality was noted between the AD and ALD groups (Figure 3) .
Comparison of response to therapy between the AD and ALD groups The pruritus scores and number of affected body sites of the dogs taken across at least four revisits (i.e. during treatment) were used as parameters to assess response to therapy between the groups. There was no significant difference (Wilcoxon-Mann-Whitney Utest; P = 0.949) in the mean pruritus score of the dogs in the AD (4.7 AE 1.4; range: 1.1-10) and ALD (4.7 AE 1.9; range = 2.8-7.1) groups during treatment (Figure 4a ). When the pruritus scores were categorized in severity levels, most dogs in the AD (51.6%) and ALD (68.8%) had moderate pruritus. There were no significant differences between the groups (Fisher's exact test; P = 0.528) in the frequencies of cases classified as having mild, moderate or severe pruritus levels (Figure 4b ).
There was no significant difference (Wilcoxon-MannWhitney U-test; P = 0.093) in the mean number of affected body sites between the AD (3.0 AE 1.2; range: 0.4-8.5) and the ALD (3.0 AE 1.4; range = 1-5.8) groups during treatment ( Figure 5 ).
No significant difference was noted between the groups in the reduction of pruritus level (marginal linear regression model; P = 0.061) or number of body sites affected (marginal linear regression model; P = 0.365) during treatment. 
Discussion
In the present study, ALD comprised 14.62% of the enrolled population. This incidence is lower than a previous report of 25.6% for dogs; 14 by comparison, the reported incidence is 10-45% in humans with IAD.
2,21-24
Moreover, in contrast to humans where females appear to be at increased risk for developing both, IAD and EAD, 1,3,23-25 neither our study nor a previous study 14 found a significant difference in sex distribution within the groups. We observed an earlier mean age of onset in ALD dogs compared to AD (16.2 versus 20.9 months); however, this difference was not statistically significant. A previous study reports the mean age of onset to be identical in both groups. 14 In contrast, human patients with IAD are known to have a later disease onset compared to EAD, even though IAD remains more common in children than adults. 1, 3, 8, 24 In humans, IAD is typically not associated with other atopic diseases, such as asthma, rhino-conjunctivitis and contact dermatitis. 1, 2, 6, 24 No differences were found between the groups regarding the presence of respiratory signs and conjunctivitis, which were infrequent in our canine patients. Conjunctivitis was observed in 18.6% of all enrolled dogs and similar results have been reported elsewhere. 26 In another study, the frequency of allergic conjunctivitis in atopic dogs was 60%, suggesting that conjunctivitis could in fact be underdiagnosed in this disease. 27 Studies evaluating breed predisposition to AD show marked regional variations, [28] [29] [30] [31] [32] [33] [34] yet the Labrador retriever has been frequently reported in various studies from different locations, 28, [32] [33] [34] so our results are in accordance with previous studies. The other overrepresented breeds in our study were the soft-coated wheaten terrier, English bulldog and American Staffordshire terrier. In one study performed in Australia, the English bulldog and American Staffordshire terrier also were shown to be at increased risk for developing AD; 33 in a worldwide multicentre study, bulldogs (English and French combined) were overrepresented. 35 In addition, one study from Switzerland reported an over-representation of soft-coated wheaten terriers and American Staffordshire terriers. 34 Not surprisingly, the breeds over-represented in the AD group were the same ones observed in the whole study population because this group accounted for 85.38% of the cases. The French bulldog was overrepresented in an ALD cohort investigated previously. 14 The present study did not find any overrepresented breeds in the ALD group, again indicating regional differences.
Human patients with IAD have been reported to have significantly lower SCORAD scores, which measures the severity of skin lesions, compared to EAD. 1, 8 Moreover, in a study, IAD patients used tacrolimus, emollients and antihistamines significantly less frequently and reported a better quality of life than EAD patients, suggesting less severe disease in this subtype. 1 In the present study, we used number of body sites affected and pruritus scores at the first visit and maintenance treatment scores as surrogates of disease severity. No significant differences in any of these variables were found between the groups. Likewise, a previous study did not find any significant differences in clinical scores between the ALD and AD groups, but no specific information on the scores used was provided.
14 These results suggest that, in contrast to humans, disease severity is similar in dogs with AD and ALD. However, prospective studies including larger numbers of dogs, especially with ALD, are needed to corroborate this hypothesis.
In humans, IAD patients seem to present more frequently with Dennie-Morgan infraorbital folds, orbital darkening, cheilitis and anterior neck folds than EAD patients. 1, 2, 6 Because of the retrospective nature of the study, we were not able to evaluate if certain disease features occur more frequently in one group than the other, nevertheless, this should be evaluated in prospective studies.
Pruritus scores and body sites affected also were evaluated following treatment as indirect indicators of response to therapy. No significant differences between the groups were noted in mean pruritus scores and number of body sites affected or reduction of pruritus and affected areas during treatment. A previous study did not observe any difference in response to glucocorticoids but noted that significantly more AD dogs had good response to ciclosporin compared to ALD dogs (92% and 50%, respectively). 14 Finally, in humans, IAD has been shown to be a dynamic disease where individuals could develop allergen-specific antibody at a latter disease phase. [5] [6] [7] [8] 36 The ALD patients included in the study were not retested, thus we do not know if this phenomenon occurs in dogs and it will be interesting to investigate this further.
This study has some limitations inherent to its retrospective nature, including the inability to assess and compare lesion severity and disease phenotype between the groups due to the lack of standardization in the lesion description portion of the medical records. Moreover, the small number of dogs in the ALD could have impacted the results. Furthermore, it could be contended that ideally all of the dogs in the AD group should have had positive tests to both IDT and AST, and that this may have provided a more precise comparison of the groups. Likewise, it could be contended that comparison of the two groups in which no cases showed a partial response to food trials (as in the AD group), may have given a more precise assessment of AD versus ALD.
In summary, in the present study, the soft-coated wheaten terrier, American Staffordshire terrier, English bulldog and Labrador retriever were over-represented in the AD group. No significant differences in age of disease onset, sex, presence of respiratory and ocular signs, percentage of time spent indoors, disease severity and response to therapy were observed between AD and ALD subtypes. The lack of differences could suggest that there are no real differences between the proposed subtypes and, that in fact, they are part of the same dynamic disease. However, future prospective studies including a larger cohort of dogs with AD, and especially with ALD, are needed to support our findings. In addition, such studies should evaluate carefully any differences in disease phenotype, barrier integrity and immunological responses between the subtypes which could help tailor therapy more effectively. 
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R esum e Contexte -Peu de donn ees est disponible pour la description des caract eristiques de la dermatite atopielike (ALD) compar e a la dermatite atopique (AD). Objectifs -Comparer les donn ees d emographiques, la s ev erit e de l'atteinte et la r eponse au traitement entre les chiens ALD et AD. Resumen Introducci on -se dispone de informaci on escasa describiendo las caracter ısticas de la dermatitis similar a la dermatitis at opica canino (ALD) en comparaci on con la dermatitis at opica propiamente dicha (AD). Objetivos -comparar los datos demogr aficos, la gravedad de la enfermedad y la respuesta al tratamiento entre perros con ALD y AD. Animales -se seleccionaron retrospectivamente doscientos cincuenta y tres perros at opicos con resultados positivos espec ıficos de alergeno de pruebas intrad ermicos y de IgE s erica. M etodos y materiales -los perros fueron incluidos en el grupo ALD si ambas pruebas de IgE fueron negativas y en el grupo AD si al menos una prueba fue positiva. Los datos demogr aficos, el nivel de prurito y la cantidad de sitios corporales afectados antes y durante la terapia, adem as de los protocolos de terapia de mantenimiento, se compararon entre los grupos.
Resultados -hubo 216 (85,38%) perros en el grupo de AD y 37 (14,62%) en el grupo de ALD. Las razas Soft Coated Wheaten Terrier, American Staffordshire Terrier, English Bulldog y Labrador Retriever estaban sobrerrepresentadas en el grupo AD. No se observaron diferencias significativas entre los grupos con respecto a las otras variables demogr aficas evaluadas. No hubo diferencias en los valroes medios de prurito y en el n umero de sitios corporales afectados en la primera visita o durante el tratamiento. Adem as, no se observaron diferencias significativas entre los grupos para los valores de tratamiento de mantenimiento y la reducci on del nivel de prurito y la cantidad de sitios corporales afectados durante el tratamiento. Conclusiones y significaci on cl ınica -las razas Soft Coated Wheaten Terrier, American Staffordshire Terrier, English Bulldog y Labrador Retriever estaban sobrerrepresentadas en el grupo de AD. No se observaron diferencias significativas en los otros datos demogr aficos y caracter ısticas cl ınicas entre los perros con ALD y AD en el presente estudio.
Zusammenfassung
Hintergrund -Es gibt nur wenig Information € uber die charakteristischen Merkmale von Atopie-€ ahnlicher Dermatitis (ALD) beim Hund im Vergleich zur atopischen Dermatitis (AD). Ziele -Ein Vergleich von ALD und AD bei Hunden in Bezug auf die demografischen Daten, die Schwere der Erkrankung und die Reaktion auf eine Therapie. Tiere -Zweihundertdreiundf€ unfzig atopische Hunde mit einem Intradermaltest Ergebnis und einem Allergen-spezifischen IgE Serologietest Ergebnis wurden retrospektiv ausgew€ ahlt. Methoden und Materialien -Die Hunde wurden der ALD Gruppe zugeteilt wenn beide IgE Tests negativ waren und in die AD Gruppe wenn mindestens ein Test positiv war. Die demografischen Daten, das Juckreizlevel und die Anzahl der betroffenen K€ orperstellen vor und w€ ahrend der Therapie, sowie die Protokolle der Erhaltungstherapie wurden zwischen den beiden Gruppen verglichen. Ergebnisse -Es waren 216 (85,38%) Hunde in der AD Gruppe und 37 (14,62%) in der ALD Gruppe. Der Soft-Coated Wheaten Terrier, der American Staffordshire Terrier, die Englische Bulldogge und der Labrador Retriever waren in der AD Gruppe € uberrepr€ asentiert. Es bestanden keine signifikanten Unterschiede zwischen den Gruppen in Bezug auf die anderen untersuchten demografischen Variablen. Es gab keine Unterschiede zwischen den durchschnittlichen Juckreizwerten und der Anzahl der betroffenen K€ orperstellen beim Erstbesuch oder w€ ahrend der Behandlung. Weiters gab es keine signifikanten Unterschiede zwischen den Gruppen in Bezug auf die Werte der Erhaltungstherapie und der Reduktion der Juckreizlevels und der Anzahl der betroffenen K€ orperstellen w€ ahrend der Behandlung. Schlussfolgerungen und klinische Bedeutung -Der Soft-Coated Wheaten Terrier, der American Staffordshire Terrier, die Englische Bulldogge und der Labrador Retriever waren in der AD Gruppe € uberrepr€ asentiert. Bei den anderen demografischen Daten und den klinischen Merkmalen gab es zwischen den Hunden mit ALD und AD in der vorliegenden Studie keine signifikanten Unterschiede.
要約 背景 -アトピー性皮膚炎(AD)と比較して犬アトピー様皮膚炎(ALD)の特徴を記述した情報は限られてい る。 目的 -本研究の目的は、ALD及びAD犬間の人口統計学的データ、疾患の重症度および治療反応を比較す ることである。
